View Older Stories
-
Johnson & Johnson (JNJ) PT Raised to $278 at BofA Securities
-
UBS Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
J&J lung cancer drug combo shows low side effect rates in study
-
Johnson & Johnson lung cancer drug shows 34-month survival in phase 3 trial
-
Johnson & Johnson gets CE mark for Acuvue Oasys MAX 2-Week lens
-
Johnson & Johnson to present neuropsychiatry data at Psych Congress 2026
-
FDA: issues early alert on Abiomed heart pump controller purge cassette issue
-
Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
-
Intuitive Surgical: Oppenheimer now bullish, sees competition being "crowded out"
-
Morgan Stanley tracks US drug market prescriptions for week ending July 31
-
Johnson & Johnson (JNJ) PT Raised to $287 at Guggenheim
-
Johnson & Johnson (JNJ) PT Raised to $280 at Raymond James
-
Microsoft joins, Broadcom exits Goldman's top-stocks list
-
Goldman Monthly Update to US Director's Cut List
-
Johnson & Johnson (JNJ) call put ratio 1 call to 1 put unto J&J to settle ovarian talc claims
-
Johnson & Johnson agrees to $5.5B settlement of ovarian talc claims
-
FDA clears Johnson & Johnson's Ottava robotic surgical system
-
Freedom Capital Upgrades Johnson & Johnson (JNJ) to Buy
-
Johnson & Johnson (JNJ) PT Raised to $261 at Bernstein SocGen
-
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; raises guidance
-
Johnson & Johnson Q2 earnings preview: analysts eye product launch progress
-
Johnson & Johnson (JNJ) call put ratio 1.6 calls to 1 put into quarter results
-
Johnson & Johnson (JNJ) call put ratio 1.5 calls to 1 put into quarter results
-
Johnson & Johnson (JNJ) call put ratio 2.8 calls to 1 put into quarter results
-
Increasing unusual put volume: AEVA SOLS LI TAP MTUM VSAT CMPS FPS CBRL JNJ NTAP
-
Increasing unusual put volume: XLI EQT ARKG ROST WEN KOS BKLN UUP DB DJ JNJ LOW FVRR
-
DePuy Synthes names Christina Zamarro as CFO, effective July 2026
-
J&J presents new IMAAVY data for myasthenia gravis at EAN 2026
-
Johnson & Johnson (JNJ) PT Raised to $270 at Guggenheim
-
Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
-
Johnson & Johnson invests $1 billion in Jacksonville vision manufacturing
-
Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
-
Leerink highlights drug demand rebound after Memorial Day
-
Johnson & Johnson expands US availability of TECNIS PureSee IOL
-
Johnson & Johnson reports positive results for rare blood disorder treatment
-
Johnson & Johnson faces $32 million verdict in Los Angeles asbestos case
-
Johnson & Johnson reports nipocalimab shows stronger response in Sjögren's patients
-
J&J's RYBREVANT plus LAZCLUZE shows 3.5-year survival in lung cancer study
-
Johnson & Johnson TECVAYLI shows survival benefits in myeloma study
-
DePuy Synthes signs exclusive distribution deal with CGBIO for bone graft
-
FDA approves accord Biopharma's Immgolis, a biosimilar to Simponi
-
Johnson & Johnson survey finds bladder cancer treatments impact patient quality of life
-
Leerink Partners Upgrades Johnson & Johnson (JNJ) to Outperform
-
Johnson & Johnson launches Shockwave C2 Aero coronary catheter globally
-
Johnson & Johnson presents neuropsychiatry data at medical conferences
-
Protagonist Therapeutics (PTGX) PT Raised to $137 at Citizens
-
Johnson & Johnson's TREMFYA shows efficacy in perianal fistulizing Crohn's
-
Johnson & Johnson reports positive phase 2b results for experimental IBD therapy
-
Johnson & Johnson reports clinical trial results for robotic surgery system


